Research ArticleNanoparticle formulations of Decoquinate (cas 18507-89-6) increase antimalarial efficacy against liver stage Plasmodium infections in mice
-
Add time:09/09/2019 Source:sciencedirect.com
Decoquinate (cas 18507-89-6) has potent activity against both Plasmodium hepatic development and red cell replication when tested in vitro. Decoquinate, however, is practically insoluble in water. To achieve its maximal in vivo efficacy, we generated nanoparticle formulations of decoquinate with a mean particle size less than 400 nm. Three separate preparations at doses of decoquinate 0.5-5 mg/kg were examined in mice infected with Plasmodium berghei. Oral administration of nanoparticle decoquinate at a dose of 1.25 mg/kg effectively inhibited the liver-stage parasite growth and provided complete causal prophylactic protection. This efficacy is 15 fold greater than that observed for microparticle decoquinate, which requires minimal dose of 20 mg/kg for the same inhibitory effect. Further in vitro studies utilizing dose–response assays revealed that decoquinate nanoformulation was substantially more potent than decoquinate microsuspension in killing both liver and blood stage malarial parasites, proving its potential for therapeutic development.
We also recommend Trading Suppliers and Manufacturers of Decoquinate (cas 18507-89-6). Pls Click Website Link as below: cas 18507-89-6 suppliers
Prev:Straightforward conversion of Decoquinate (cas 18507-89-6) into inexpensive tractable new derivatives with significant antimalarial activities
Next:Efficacy of Decoquinate (cas 18507-89-6) against drug sensitive laboratory strains of Eimeria tenella and field isolates of Eimeria spp. in broiler chickens in China) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Decoquinate (cas 18507-89-6) induces tissue cyst formation by the RH strain of Toxoplasma gondii09/27/2019
- Efficacy of Decoquinate (cas 18507-89-6) against Neospora caninum tachyzoites in cell cultures09/26/2019
- Short communicationActivity of Decoquinate (cas 18507-89-6) against Cryptosporidium parvum in cell cultures and neonatal mice09/25/2019
- Tracing the emergence of drug-resistance in coccidia (Eimeria spp.) of commercial broiler flocks medicated with Decoquinate (cas 18507-89-6) for the first time in the United Kingdom09/24/2019
- Efficacy of Decoquinate (cas 18507-89-6) against drug sensitive laboratory strains of Eimeria tenella and field isolates of Eimeria spp. in broiler chickens in China09/10/2019
- Straightforward conversion of Decoquinate (cas 18507-89-6) into inexpensive tractable new derivatives with significant antimalarial activities09/08/2019
- Original articleDecoquinate (cas 18507-89-6) derivatives: A new class of potent antischistosomal agents against Schistosoma japonicum09/07/2019
- Efficacy of Decoquinate (cas 18507-89-6) against Sarcocystis neurona in cell cultures09/06/2019
- Research paperRepurposing of commercially available anti-coccidials identifies diclazuril and Decoquinate (cas 18507-89-6) as potential therapeutic candidates against Besnoitia besnoiti infection09/05/2019